IS5969A - Samsett lyfjameðferð - Google Patents

Samsett lyfjameðferð

Info

Publication number
IS5969A
IS5969A IS5969A IS5969A IS5969A IS 5969 A IS5969 A IS 5969A IS 5969 A IS5969 A IS 5969A IS 5969 A IS5969 A IS 5969A IS 5969 A IS5969 A IS 5969A
Authority
IS
Iceland
Prior art keywords
combination chemotherapy
chemotherapy
combination
Prior art date
Application number
IS5969A
Other languages
English (en)
Inventor
Carleton Gowan Richard
Sebolt-Leopold Judith
Original Assignee
Warner-Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company, , Delaware Corporation filed Critical Warner-Lambert Company, , Delaware Corporation
Publication of IS5969A publication Critical patent/IS5969A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Seasonings (AREA)
IS5969A 1998-12-22 2001-06-14 Samsett lyfjameðferð IS5969A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22
US16478899P 1999-11-10 1999-11-10
PCT/US1999/030485 WO2000037141A1 (en) 1998-12-22 1999-12-21 Combination chemotherapy

Publications (1)

Publication Number Publication Date
IS5969A true IS5969A (is) 2001-06-14

Family

ID=26810891

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5969A IS5969A (is) 1998-12-22 2001-06-14 Samsett lyfjameðferð

Country Status (31)

Country Link
EP (1) EP1140291B1 (is)
JP (1) JP2002532570A (is)
KR (1) KR20010099877A (is)
CN (1) CN1333698A (is)
AP (1) AP2001002175A0 (is)
AT (1) ATE310567T1 (is)
AU (1) AU2203900A (is)
BG (1) BG105715A (is)
BR (1) BR9916839A (is)
CA (1) CA2352326A1 (is)
CZ (1) CZ20012139A3 (is)
DE (1) DE69928568T2 (is)
EA (1) EA200100687A1 (is)
EE (1) EE200100339A (is)
ES (1) ES2253928T3 (is)
GE (1) GEP20043172B (is)
HK (1) HK1042057A1 (is)
HR (1) HRP20010473A2 (is)
HU (1) HUP0104844A3 (is)
ID (1) ID30250A (is)
IL (1) IL143939A0 (is)
IS (1) IS5969A (is)
MA (1) MA26768A1 (is)
NO (1) NO20013099L (is)
NZ (1) NZ512859A (is)
OA (1) OA11733A (is)
PL (1) PL348326A1 (is)
SK (1) SK8712001A3 (is)
TR (1) TR200101871T2 (is)
WO (1) WO2000037141A1 (is)
YU (1) YU45401A (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
EP1365796A2 (en) 2000-09-01 2003-12-03 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
WO2002076496A1 (en) * 2001-03-22 2002-10-03 Van Andel Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
AU2004279721A1 (en) * 2003-10-08 2005-04-21 Teijin Pharma Limited Process for producing aminopyrrolidine derivative and intermediate compound
KR101013932B1 (ko) 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 N-[(r)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
ES2444866T3 (es) 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
AU2006313701B2 (en) 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
CA2789696C (en) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CN103301096B (zh) * 2012-03-14 2015-05-06 中国中化股份有限公司 取代二苯胺类化合物作为制备抗肿瘤药物的应用
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
JP6465790B2 (ja) * 2013-02-27 2019-02-06 第一三共株式会社 Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
EP0988376A2 (en) * 1997-03-21 2000-03-29 The Board Of Regents, The University Of Texas System Noey2 gene compositions and methods of use
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression

Also Published As

Publication number Publication date
SK8712001A3 (en) 2002-02-05
IL143939A0 (en) 2002-04-21
EP1140291A1 (en) 2001-10-10
ES2253928T3 (es) 2006-06-01
CA2352326A1 (en) 2000-06-29
NO20013099L (no) 2001-08-20
PL348326A1 (en) 2002-05-20
MA26768A1 (fr) 2004-12-20
TR200101871T2 (tr) 2001-10-22
ATE310567T1 (de) 2005-12-15
EP1140291B1 (en) 2005-11-23
AP2001002175A0 (en) 2001-06-21
CZ20012139A3 (cs) 2002-01-16
HRP20010473A2 (en) 2002-08-31
GEP20043172B (en) 2004-02-25
HUP0104844A2 (en) 2002-06-29
CN1333698A (zh) 2002-01-30
KR20010099877A (ko) 2001-11-09
DE69928568T2 (de) 2006-07-27
EA200100687A1 (ru) 2001-12-24
EE200100339A (et) 2002-10-15
BR9916839A (pt) 2001-10-09
WO2000037141A9 (en) 2000-12-07
YU45401A (sh) 2004-07-15
HUP0104844A3 (en) 2003-05-28
DE69928568D1 (de) 2005-12-29
AU2203900A (en) 2000-07-12
NO20013099D0 (no) 2001-06-21
ID30250A (id) 2001-11-15
OA11733A (en) 2005-05-12
NZ512859A (en) 2004-06-25
HK1042057A1 (zh) 2002-08-02
BG105715A (en) 2002-04-30
WO2000037141A1 (en) 2000-06-29
JP2002532570A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
NL350094I2 (nl) Valifenalaat
DE69829040D1 (de) Elektroplattierungschemie
DE59914158D1 (de) Metallocenmonohalogenide
DE69911432D1 (de) Abgasrückfürungseinrichtung
DE69920962D1 (de) Polycarbonatabmischung
DE69904595D1 (de) Betacarbolinverbindungen
ID23211A (id) Sulfanilsilana
DE69908817D1 (de) Laderaum
DE69808145D1 (de) Tintenbehälternachfüllsystem
DE59902874D1 (de) Buchsenkontakt
DE69904565D1 (de) Hubventilsteuerungseinrichtung
FI980536A7 (fi) Kokoonpanolinja
DE69812868D1 (de) Flanschreformierungsanlage
ID30250A (id) Kemoterapi kombinasi
DE69919631D1 (de) Isoliermembranmontage
ID24221A (id) Tempat patrum
DE69910986D1 (de) Atmosphärenteilchenanalysator
DE69902762D1 (de) Riser-spannanordnung
DE69901068D1 (de) Estersynthese
DE69919644D1 (de) Wellenabstreifdichtung
DE59913393D1 (de) Fadenchangierung
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
DE69820261D1 (de) Steuerventilanordnnung
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
NO996073D0 (no) Hockeykoelle